RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Niemann-Pick Disease Type C: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
A Colletotrichum orbiculare-based fungal model recapitulates conserved cellular defects of Niemann–Pick type C disease and enables therapeutic evaluation
Hodaka Sano et al., Communications Biology (17 October 2026)
https://doi.org/10.1038/s42003-026-11198-5
- 2.
The Real-World Experience of Niemann-Pick Disease Type C: Patient and Caregiver Perspectives to Inform Future Therapeutic and Policy Directions
Krista Casazza et al., Research Square (13 October 2026)
https://doi.org/10.21203/rs.3.rs-9526209/v1
- 3.
Conformational switch of NPC1 epitomizes a lumen-to-membrane alternating access model for nonpolar substrates.
Wu Xuelan et al., Proceedings of the National Academy of Sciences of the United States of America (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42837444/
- 4.
Delivering the message: mRNA replacement reaches the liver in Niemann-Pick type C1 disease
Laura Lentini et al., Molecular Therapy — Nucleic Acids (7 October 2026)
https://doi.org/10.1016/j.omtn.2026.103109
- 5.
Unveiling lipid dysregulation: lipidomics of mouse brain and myelin in Niemann–Pick disease type C1
Koralege C. Pathmasiri et al., Communications Biology (7 October 2026)
https://doi.org/10.1038/s42003-026-11083-1
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07054515 · Recruiting · Phase 3 · Azafaros B.V.
Ages 4 and over
https://clinicaltrials.gov/study/NCT07054515
- 2.
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725 · Recruiting · Phase 3 · Azafaros B.V.
Ages 4 and over
https://clinicaltrials.gov/study/NCT07082725
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Niemann-Pick Disease Type C
Niemann-Pick disease type C is a rare lysosomal storage disorder caused by mutations in NPC1 or NPC2 genes, causing progressive neurodegeneration including vertical supranuclear gaze palsy, ataxia, dementia, and seizures. Miglustat can slow neurological progression, and hydroxypropyl beta-cyclodextrin is in clinical trials.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Abstract Niemann–Pick type C disease is a fatal lysosomal storage disorder caused by mutations in NPC1 or NPC2 , leading to lipid accumulation and progressive neurodegeneration. Current mammalian models recapitulate major pathological features but are limited by long disease courses and low throughput. Here, we establish the plant-pathogenic fungus Colletotrichum orbiculare as a scalable eukaryotic model of Niemann–Pick type C disease. Introduction of disease-associated mutations into fungal NPC1 or NPC2 homologs abolishes pathogenicity, showing that NPC dysfunction compromises lipid-dependent morphogenesis required for host penetration. Conversely, human NPC1 partially restores fungal infection. Together, these findings support functional conservation of NPC-dependent cellular processes across kingdoms. Miglustat and 2-hydroxypropyl-β-cyclodextrin restore pathogenicity through distinct lipid pathways. These complementary modes of rescue indicate that NPC1 and NPC2 dysfunction converges on lipid-dependent morphogenesis closely linked to actin organization. By connecting lipid metabolism, actin organization, and pharmacological rescue to a measurable infection outcome, this fungal model provides a tractable and scalable platform for mechanistic and therapeutic exploration.
Common Questions
What is Niemann-Pick Disease Type C?
Niemann-Pick disease type C is a rare lysosomal storage disorder caused by mutations in NPC1 or NPC2 genes, causing progressive neurodegeneration including vertical supranuclear gaze palsy, ataxia, dementia, and seizures. Miglustat can slow neurological progression, and hydroxypropyl beta-cyclodextrin is in clinical trials.
How many clinical trials are available for Niemann-Pick Disease Type C?
RareWays currently indexes 33 clinical trials for Niemann-Pick Disease Type C, of which 3 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Niemann-Pick Disease Type C come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Niemann-Pick Disease Type C.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.